Phaseline

Targets › RHO

RHO (Rhodopsin): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 3; Ophthalmology; next expected readout Feb 2027.

G protein-coupled photoreceptor that activates the G protein transducin (t) signaling pathway in response to light and is essential for image-forming vision under low-light conditions. Required for postnatal photoreceptor cell viability. (UniProt, P08100)

Open in Phaseline: the race on RHO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OcugenOCU400
Gene therapy vector for retinitis pigmentosa and Leber congenital amaurosis
RHO, NR2E3, CEP290Phase 3Retinitis PigmentosaFeb 2027
Chigenovo Co., LtdZVS203e
rAAV8-delivered SauriCas9 with sgRNA targeting RHO gene mutations
RHOPhase 1Retinitis PigmentosaJun 2030
ProQR TherapeuticsQR-1123
RNA therapeutic targeting P23H mutation in RHO gene (antisense oligonucleotide or similar
RHOPhase 1Autosomal Dominant Retinitis Pigmentosa–

Conditions

Retinitis Pigmentosa (3) Autosomal Dominant Retinitis Pigmentosa (1)

Modalities

small molecule (2), other (1)

Companies

Ocugen (1) Chigenovo Co., Ltd (1) ProQR Therapeutics (1)

Related targets

NR2E3 (1) CEP290 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.